PRLD Latest Press Releases

-- May 12, 2026 --

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 7:01 AM

-- April 20, 2026 --

Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering Globe Newswire 6:30 AM

Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026 Globe Newswire 6:00 AM

-- April 15, 2026 --

Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer Globe Newswire 7:30 AM

-- March 17, 2026 --

Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting Globe Newswire 4:31 PM

-- March 10, 2026 --

Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026 Globe Newswire 7:01 AM

-- February 5, 2026 --

The $71 Billion Cancer Shift: Why The FDA Is Speeding Up Globe Newswire 9:26 AM

-- February 3, 2026 --

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor Globe Newswire 9:00 AM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software